These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33083701)

  • 1. Expected vs Actual Outcomes of Elective Initiation of Inotropic Therapy During Heart Failure Hospitalization.
    Snipelisky D; Fudim M; Perez A; Nayor M; Lever NM; Raymer DS; Rosenbaum AN; AbouEzzeddine O; Hernandez AF; Stevenson LW; Gilstrap LG
    Mayo Clin Proc Innov Qual Outcomes; 2020 Oct; 4(5):529-536. PubMed ID: 33083701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
    Gilstrap LG; Fonarow GC; Desai AS; Liang L; Matsouaka R; DeVore AD; Smith EE; Heidenreich P; Hernandez AF; Yancy CW; Bhatt DL
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28189999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
    Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS
    Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the ventricular assist device programme in the UK.
    Sharples L; Buxton M; Caine N; Cafferty F; Demiris N; Dyer M; Freeman C
    Health Technol Assess; 2006 Nov; 10(48):1-119, iii-iv. PubMed ID: 17134596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study.
    Houchen E; Loefroth E; Schlienger R; Proudfoot C; Corda S; Saha S; Satwase SK; Studer R
    Cardiol Ther; 2022 Mar; 11(1):113-127. PubMed ID: 35094306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study.
    Hsiao FC; Lin CP; Yu CC; Tung YC; Chu PH
    Front Cardiovasc Med; 2022; 9():794707. PubMed ID: 35360037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
    Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
    JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiology.
    Kalogeropoulos AP; Marti CN; Georgiopoulou VV; Butler J
    J Card Fail; 2014 Aug; 20(8):593-601. PubMed ID: 24879975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series.
    Taghavi S; Chenaghlou M; Mirtajaddini M; Amin A; Naderi N
    J Cardiovasc Thorac Res; 2020; 12(4):334-336. PubMed ID: 33510884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
    Zhao M; Xin Y; Li J; Cao X; Liu X
    Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-Discharge Initiation of Angiotensin Receptor-Neprilysin Inhibitor in an Inotrope-Dependent Patient in the Outpatient Setting: A Case Report.
    Ling H; Patel N; Egolum UO
    Hosp Pharm; 2021 Dec; 56(6):702-705. PubMed ID: 34732925
    [No Abstract]   [Full Text] [Related]  

  • 14. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Fonarow GC; DeVore AD; Sharma PP; Vaduganathan M; Albert NM; Duffy CI; Hill CL; McCague K; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Butler J
    J Am Coll Cardiol; 2019 May; 73(19):2365-2383. PubMed ID: 30844480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines.
    Allen LA; Fonarow GC; Grau-Sepulveda MV; Hernandez AF; Peterson PN; Partovian C; Li SX; Heidenreich PA; Bhatt DL; Peterson ED; Krumholz HM;
    Circ Heart Fail; 2014 Mar; 7(2):251-60. PubMed ID: 24488983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of early initiation of sacubitril-valsartan therapy in patients with acute decompensated heart failure].
    Si JP; Chen YW; Yang J; Li X; Zhang YL; Liu JQ; Guo R; Wang K; Jiang YN; Xia YL; Liu Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jun; 48(6):477-483. PubMed ID: 32842257
    [No Abstract]   [Full Text] [Related]  

  • 17. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
    Książczyk M; Lelonek M
    Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dobutamine as bridge to angiotensin-converting enzyme inhibitor-nitrate therapy in endstage heart failure.
    Levine TB; Levine AB; Elliott WG; Narins B; Stomel RJ
    Clin Cardiol; 2001 Mar; 24(3):231-6. PubMed ID: 11288970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes.
    López-Candales AL; Carron C; Schwartz J
    Clin Cardiol; 2004 Jan; 27(1):23-8. PubMed ID: 14743852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.